CSIMarket Company Name, Ticker, Customers, else..
 
Alto Neuroscience Inc   (NYSE: ANRO)
 
Price: $30.9500 $0.70 2.314%
Day's High: $31.18000030517578 Week Perf: -2.3 %
Day's Low: $ 30.09 30 Day Perf: -7.89 %
Volume (M): 72,708 52 Wk High: $ 37.48
Volume (M$): $ 0 52 Wk Avg: $20.12
Open: $30.50 52 Wk Low: $3.59



 Market Capitalization (Millions $) 1,325
 Shares Outstanding (Millions) 43
 Employees 68
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -84
 Cash Flow (TTM) (Millions $) 116
 Capital Exp. (TTM) (Millions $) 1

Business Description


The company is a clinical-stage biopharmaceutical firm developing treatments for neuropsychiatric disorders using a proprietary Precision Psychiatry Platform. Its pipeline includes seven clinical-stage assets targeting major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, and Parkinson's disease. The company utilizes neurobiological data and biomarkers to identify patients likely to respond to its therapies, with the goal of improving outcomes in psychiatry through precision medicine.


   Company Address: 650 Castro Street, Suite 450 Mountain View 94041 CA
   Company Phone Number: 200-0412   Stock Exchange / Ticker: NYSE ANRO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALZN        9.23% 
ATAI        0.14% 
CMPS   -9.03%    
ENVB        1.03% 
INDV   -2.1%    
VTGN   -1.29%    
• View Complete Report
   



Business Update

Financing Innovation Alto Neuroscience’s Strategic $50 Million Private Placement Aiming to Pioneer Neuropsychiatric...

Published Mon, Oct 20 2025 11:51 AM UTC

Enhancing the field of neuropsychiatric treatment is paramount in addressing the growing global mental health crisis. This article explores the recent $50 million private placement financing by Alto Neuroscience, a clinical-stage biopharmaceutical company. With a specific focus on developing precision medicines for neuropsychiatric disorders, Alto s financial maneuver sign...
Announcement

Alto Neuroscience Faces Legal Challenges Amid Investor Concerns Class Action Lawsuit & Investigations Unfold

Published Thu, Sep 11 2025 6:13 AM UTC

In the ever-evolving landscape of biotechnology and pharmaceuticals, the spotlight often shines brightly on companies that promise innovative solutions to pressing health challenges. Alto Neuroscience, Inc., a biotech firm listed on the New York Stock Exchange under the ticker symbol ANRO, recently found itself at the center of significant legal scrutiny, a development that ...
Announcement

Capsules of Controversy Lessons in Transparency from Alto Neurosciences Legal Challenges,

Published Wed, Sep 10 2025 12:19 PM UTC

: The pharmaceutical industry, characterized by its rapid advancements and critical role in healthcare, demands transparency and accuracy in the dissemination of information. Recent legal challenges faced by Alto Neuroscience, Inc. (NYSE: ANRO) underscore the potential repercussions of allegedly misleading stakeholders regarding clinical and commercial prospects. This artic...
Announcement

The Deadline Approaches Alto Neuroscience Investors Urged to Take Action Amid Market Volatility,

Published Thu, Aug 28 2025 11:07 AM UTC

The Crucial Deadline for Alto Neuroscience Investors: A Call to Action from Rosen Law FirmIn a world where the stock market constantly fluctuates, investors in Alto Neuroscience, Inc. (NYSE: ANRO) face a pivotal moment. As the company’s shares have garnered attention for lagging behind the overall market throughout August, the time to act is now. The Rosen Law Firm, an es...
Business Update

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

Published Wed, Dec 11 2024 2:47 PM UTC

Alto Neuroscience: Progress Amidst Challenges at the 63rd Annual ACNP MeetingAlto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company dedicated to the development of innovative precision medicines for neuropsychiatric disorders, made significant waves at the 63rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held from Dece...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 6.04
PEG (TTM) -

Financial Strength Current
Quick Ratio 14.64
Working Capital Ratio 14.85
Leverage Ratio (MRQ) 0.16
Total Debt to Equity 0.09
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.53 $
Revenues (TTM) -
Cash Flow (TTM) 2.71 $
Cash 5.69 $
Book Value 5.12 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,238,794
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.